TY - JOUR
T1 - Long-term risk for subsequent leukemia after treatment for childhood cancer
T2 - A report from the Childhood Cancer Survivor Study
AU - Nottage, Kerri
AU - Lanctot, Jennifer
AU - Li, Zhenghong
AU - Neglia, Joseph P.
AU - Bhatia, Smita
AU - Hammond, Sue
AU - Leisenring, Wendy
AU - Meadows, Anna
AU - Srivastava, Deokumar
AU - Robison, Leslie L.
AU - Armstrong, Gregory T.
PY - 2011/6/9
Y1 - 2011/6/9
N2 - Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred ≥ 15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95% confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia ≥ 15 years from primary diagnosis of childhood cancer.
AB - Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred ≥ 15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95% confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia ≥ 15 years from primary diagnosis of childhood cancer.
UR - http://www.scopus.com/inward/record.url?scp=79959402991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959402991&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-02-335158
DO - 10.1182/blood-2011-02-335158
M3 - Article
C2 - 21498675
AN - SCOPUS:79959402991
SN - 0006-4971
VL - 117
SP - 6315
EP - 6318
JO - Blood
JF - Blood
IS - 23
ER -